Taro Pharmaceutical Launches AB-Rated Perampanel Oral Suspension as Generic Alternative to Fycompa

Formulary committees and pharmacy directors now have an AB-rated generic option for perampanel oral suspension following Taro Pharmaceutical Industries' commercial launch of its 0.5 mg/mL formulation, a therapeutic equivalent to Eisai's FYCOMPA oral suspension.

The product is a white to off-white, homogenous suspension supplied in a 340 mL bottle under NDC 51672-4256-9. The AB therapeutic equivalence rating confirms the FDA has determined the generic meets the bioequivalence and pharmaceutical equivalence standards required for substitution at the dispensing level without prescriber intervention, a threshold that carries direct weight in state-level substitution law compliance and P&T committee review cycles.

For QA and regulatory leads at 503B outsourcing facilities that have been compounding perampanel suspension to address access gaps, the AB-rated commercial entry reframes the compounding rationale. FDA policy generally restricts compounding of drug products that are commercially available and not on the drug shortage list; the Taro launch warrants a prompt review of any active compounding programs for this formulation against current 21 CFR Part 503B requirements.

On the antiepileptic generics landscape, perampanel oral suspension serves a pediatric and dysphagic patient population where liquid formulations carry outsized clinical relevance. Taro's entry introduces price competition into a segment previously held by the branded reference product, with downstream implications for Medicaid reimbursement benchmarks and commercial formulary tier placement.

P&T committees evaluating formulary substitution should confirm state board of pharmacy substitution permissions align with the AB rating before updating dispensing protocols.

Source: Taro Pharmaceutical Industries via taro.com, July 8, 2026.